Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
J Drugs Dermatol. 2006 Mar; 5(3):262-6.JD

Abstract

BACKGROUND

Immunotherapy with sqauric acid dibutyl ester (SADBE) is a well-accepted therapy for alopecia areata.

OBJECTIVE

To study efficacy, safety, and factors influencing the outcome in the treatment of alopecia areata.

METHOD

During a 4-year period, 70 patients of alopecia areata, unresponsive to conventional therapies, were treated with SADBE for a period of 4 months and thereafter depending on the response with initial therapy. The percent scalp hair loss was calculated using "Severity of Alopecia Tool" (SALT) score before and after the therapy.

RESULTS

Out of 70 patients, 6 were lost to follow-up and 4 could not develop sensitization; therefore, data of 60 patients was available for analysis. The overall success rate was 43%. In patients with <50% scalp involvement; the success rate was better (68%) than in those with >50% involvement (29%). The response was better in patients with late onset and shorter duration of disease. Family history of alopecia areata or other autoimmune diseases, personal or family history of atopy, presence of auto antibodies in serum, and presence of nail changes were associated with poorer prognosis. Out of 26 patients who responded, relapse occurred in 21 (81%) patients.

CONCLUSION

In conclusion, SADBE is an effective and well-tolerated mode of therapy in Indian patients of AA, although the long-term results of SADBE were not encouraging.

Authors+Show Affiliations

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

16573260

Citation

Ajith, C, et al. "Efficacy and Safety of the Topical Sensitizer Squaric Acid Dibutyl Ester in Alopecia Areata and Factors Influencing the Outcome." Journal of Drugs in Dermatology : JDD, vol. 5, no. 3, 2006, pp. 262-6.
Ajith C, Gupta S, Kanwar AJ. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome. J Drugs Dermatol. 2006;5(3):262-6.
Ajith, C., Gupta, S., & Kanwar, A. J. (2006). Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome. Journal of Drugs in Dermatology : JDD, 5(3), 262-6.
Ajith C, Gupta S, Kanwar AJ. Efficacy and Safety of the Topical Sensitizer Squaric Acid Dibutyl Ester in Alopecia Areata and Factors Influencing the Outcome. J Drugs Dermatol. 2006;5(3):262-6. PubMed PMID: 16573260.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome. AU - Ajith,C, AU - Gupta,Somesh, AU - Kanwar,Amrinder Jit, PY - 2006/4/1/pubmed PY - 2006/6/6/medline PY - 2006/4/1/entrez SP - 262 EP - 6 JF - Journal of drugs in dermatology : JDD JO - J Drugs Dermatol VL - 5 IS - 3 N2 - BACKGROUND: Immunotherapy with sqauric acid dibutyl ester (SADBE) is a well-accepted therapy for alopecia areata. OBJECTIVE: To study efficacy, safety, and factors influencing the outcome in the treatment of alopecia areata. METHOD: During a 4-year period, 70 patients of alopecia areata, unresponsive to conventional therapies, were treated with SADBE for a period of 4 months and thereafter depending on the response with initial therapy. The percent scalp hair loss was calculated using "Severity of Alopecia Tool" (SALT) score before and after the therapy. RESULTS: Out of 70 patients, 6 were lost to follow-up and 4 could not develop sensitization; therefore, data of 60 patients was available for analysis. The overall success rate was 43%. In patients with <50% scalp involvement; the success rate was better (68%) than in those with >50% involvement (29%). The response was better in patients with late onset and shorter duration of disease. Family history of alopecia areata or other autoimmune diseases, personal or family history of atopy, presence of auto antibodies in serum, and presence of nail changes were associated with poorer prognosis. Out of 26 patients who responded, relapse occurred in 21 (81%) patients. CONCLUSION: In conclusion, SADBE is an effective and well-tolerated mode of therapy in Indian patients of AA, although the long-term results of SADBE were not encouraging. SN - 1545-9616 UR - https://www.unboundmedicine.com/medline/citation/16573260/Efficacy_and_safety_of_the_topical_sensitizer_squaric_acid_dibutyl_ester_in_Alopecia_areata_and_factors_influencing_the_outcome_ L2 - http://www.diseaseinfosearch.org/result/313 DB - PRIME DP - Unbound Medicine ER -